Skip to main content

Table 1 Characteristics of RA patients for whom analysis of IL-17-positive CD4 T cells in paired blood and synovial fluid (top), and paired blood and synovium (bottom) was performed.

From: Rheumatoid synovial fluid interleukin-17-producing CD4 T cells have abundant tumor necrosis factor-alpha co-expression, but little interleukin-22 and interleukin-23R expression

     Treatment     % CD3+CD4+
IL17+
Subject RF ACPA Disease duration, years DMARD Anti-TNF Steroid ESR,
mm/hr
CRP,
mg/l
DAS28
(ESR)
PBMC SFMC
1 +ve +ve <1 MTX,
HCQ
N N 39 15 6.20 1.95 2.52
2 +ve +ve 2 MTX, HCQ N N 61 8 7.01 1.09 0.82
3 +ve +ve 1 N N N 21 7 4.18 2.36 2.17
4 +ve -ve 23 MTX N N 18 11 5.83 0.73 0.79
5 +ve -ve 45 MTX N N 60 11 5.27 0.63 0.53
6 +ve +ve 5 MTX, SSZ N N 69 93 5.48 2.34 2.84
7 +ve +ve 4 N Y Y 28 30 3.51 3.48 1.17
8 +ve +ve <1 MTX,
HCQ
N Y 63 72 6.14 1.59 1.44
9 +ve +ve 5 N Y Y 32 12 5.62 1.30 7.90
10 +ve +ve <1 MTX Y N 80 71 6.08 0.73 5.18
11 -ve +ve 1 N N N 10 15 5.76 0.86 3.48
12 +ve +ve 5 MTX Y Y 24 24 4.42 1.06 1.06
13 -ve -ve 6 HCQ N N 81 92 4.39 0.37 4.45
14 +ve +ve 1 MTX N Y 17 16 4.48 0.49 0.46
     Treatment     % CD3+CD4+
IL17+
Subject RF ACPA Disease duration, years DMARD Anti-TNF Steroid ESR,
mm/hr
CRP,
mg/l
DAS28
(ESR)
PBMC SVMC
1 +ve +ve 16 N Y N 20 20 3.83 0.77 0.55
2 +ve +ve 4 N Y Y 13 9 4.95 0.57 0.48
3 +ve +ve 5 N Y Y 13 3 4.50 1.63 0.78
4 -ve +ve 8 MTX Y N 12 0 3.57 1.49 1.08
5 +ve +ve 20 N N Y 89 24 6.03 2.63 0.91
6 +ve +ve 23 N N Y 45 57 5.86 0.08 0.24
7 +ve +ve 20 SSZ N N 31 11 4.33 0.73 0.81
8 +ve +ve 5 N Y Y 15 3 4.55 0.29 1.17
9 -ve -ve 15 N Y N 115 22 6.19 1.37 0.99
10 -ve +ve 1 LEF N N 10 15 5.76 1.65 0.48
  1. -ve, negative; +ve, positive; ACPA, anti-CCP antibodies; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; N, no; PB, peripheral blood; RF, rheumatoid factor; SF, synovial fluid; SSZ, sulfasalazine; SVMC, synovium mononuclear cells; Y, yes.